SuperworthRafael EPS RFL
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Apr 30, 2026
- −$0.69
- Latest quarter, Q3 FY26
- −$0.08
- Fiscal year 2025
- −$1.04
Rafael's earnings per share was −$0.69 over the twelve months to Apr 30, 2026.
In its latest quarter, Q3 FY26, it was −$0.08.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.04 | n/a |
| FY2024 | −$1.45 | n/a |
| FY2023 | −$0.08 | n/a |
| FY2022 | −$6.54 | n/a |
| FY2021 | −$1.46 | n/a |
| FY2020 | −$0.66 | n/a |
| FY2019 | −$0.35 | n/a |
| FY2018 | −$0.92 | n/a |
| FY2017 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.08 | n/a | −$0.69 | |
| Q2 FY26 | −$0.13 | n/a | −$0.80 | |
| Q1 FY26 | −$0.19 | n/a | −$0.86 | |
| Q4 FY25 | −$0.29 | n/a | −$1.04 | |
| Q3 FY25 | −$0.19 | n/a | −$0.94 | |
| Q2 FY25 | −$0.19 | −176% | −$2.11 | |
| Q1 FY25 | −$0.37 | n/a | −$1.67 | |
| Q4 FY24 | −$0.19 | −480% | −$1.45 | |
| Q3 FY24 | −$1.36 | n/a | −$1.21 | |
| Q2 FY24 | $0.25 | n/a | $0.09 | |
| Q1 FY24 | −$0.15 | −314% | −$0.30 | |
| Q4 FY23 | $0.05 | n/a | −$0.08 |
Against its peers
Companies in Drug Manufacturers - General nearest Rafael's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RFLRafael | −$0.69 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| Peer median | $0.52 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Rafael
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.